Biological therapy, biology, cancer, News, science news, Uncategorized

NICE approves combination immunotherapy drug for advanced skin cancer

Sometimes the science of the future seems very far away, and sometimes it seems to happen almost faster than you would think. Immunotherapy is taking off at a record pace in the search for better cancer treatments.

The National Institute for Clinical Excellence (Nice), the body in the United Kingdom that licences medicines for use, has just approved a combination of two immunotherapy drugs in record time. These two drugs are ipilumab and nivolumab, which I blogged about as a treatment showing promising clinical trial results only a short while ago.

Nivolumab blocks a molecule secreted by cancer cells that prevents the T-cells of the immune system from recognising and destroying them. Ipilumab, which was approved by Nice in 2012, stimulates the T-cells to multiply. This drug combination has been approved for the treatment of metastatic (i.e. spread from its original site) melanoma, a particularly intractable cancer to treat. The life expectancy for this type of cancer is only around two years: the combination treatment has extended this to as much as ten years (and counting, in some cases). Moreover, ipilumab alone is effective in about 20% of cases: the combination raises that to 60%. So these are massively improved odds. I expect to see more successes soon, and, as more experience is gained with these exciting new techniques, hopefully the side-effects will become more manageable as well.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s